Stocks
$11.3 Billion Merger Clears Hurdle as Bio-Techne Shareholders Back Deal with German Merck
Bio-Techne shareholders have approved an $11.3 billion merger with German Merck, paving the way for a significant deal in the biotech industry.
The news marks a major development in the sector, with both companies set to combine their operations and create a leading player in the market.
Bio-Techne's shareholders have given the green light to the merger, which is expected to complete later this year. The deal will see Bio-Techne become a subsidiary of Merck, with its CEO, D.Isaev, set to take on a key role within the combined entity.